Role of novel histone modifications in cancer

Muthu K. Shanmugam, Frank Arfuso, Surendar Arumugam, Arunachalam Chinnathambi, Bian Jinsong, Sudha Warrier, Ling Zhi Wang, Alan Prem Kumar, Kwang Seok Ahn, Gautam Sethi, Manikandan Lakshmanan

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Oncogenesis is a multistep process mediated by a variety of factors including epigenetic modifications. Global epigenetic post-translational modifications have been detected in almost all cancers types. Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence. These epigenetic modifications occur in key oncogenes, tumor suppressor genes, and transcription factors, leading to cancer initiation and progression. The most commonly observed epigenetic changes include DNA methylation, histone lysine methylation and demethylation, histone lysine acetylation and deacetylation. However, there are several other novel post-translational modifications that have been observed in recent times such as neddylation, sumoylation, glycosylation, phosphorylation, poly- ADP ribosylation, ubiquitination as well as transcriptional regulation and these have been briefly discussed in this article. We have also highlighted the diverse epigenetic changes that occur during the process of tumorigenesis and described the role of histone modifications that can occur on tumor suppressor genes as well as oncogenes, which regulate tumorigenesis and can thus form the basis of novel strategies for cancer therapy.

Original languageEnglish
Pages (from-to)11414-11426
Number of pages13
JournalOncotarget
Volume9
Issue number13
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Histone Code
Epigenomics
Neoplasms
Carcinogenesis
Post Translational Protein Processing
Tumor Suppressor Genes
Oncogenes
Histones
Lysine
Sumoylation
Ubiquitination
DNA Methylation
Acetylation
Glycosylation
Adenosine Diphosphate
Methylation
Transcription Factors
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Shanmugam, M. K., Arfuso, F., Arumugam, S., Chinnathambi, A., Jinsong, B., Warrier, S., ... Lakshmanan, M. (2018). Role of novel histone modifications in cancer. Oncotarget, 9(13), 11414-11426. https://doi.org/10.18632/oncotarget.23356
Shanmugam, Muthu K. ; Arfuso, Frank ; Arumugam, Surendar ; Chinnathambi, Arunachalam ; Jinsong, Bian ; Warrier, Sudha ; Wang, Ling Zhi ; Kumar, Alan Prem ; Ahn, Kwang Seok ; Sethi, Gautam ; Lakshmanan, Manikandan. / Role of novel histone modifications in cancer. In: Oncotarget. 2018 ; Vol. 9, No. 13. pp. 11414-11426.
@article{919a7e3f9bf847dbb1ee88e4cd1804e9,
title = "Role of novel histone modifications in cancer",
abstract = "Oncogenesis is a multistep process mediated by a variety of factors including epigenetic modifications. Global epigenetic post-translational modifications have been detected in almost all cancers types. Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence. These epigenetic modifications occur in key oncogenes, tumor suppressor genes, and transcription factors, leading to cancer initiation and progression. The most commonly observed epigenetic changes include DNA methylation, histone lysine methylation and demethylation, histone lysine acetylation and deacetylation. However, there are several other novel post-translational modifications that have been observed in recent times such as neddylation, sumoylation, glycosylation, phosphorylation, poly- ADP ribosylation, ubiquitination as well as transcriptional regulation and these have been briefly discussed in this article. We have also highlighted the diverse epigenetic changes that occur during the process of tumorigenesis and described the role of histone modifications that can occur on tumor suppressor genes as well as oncogenes, which regulate tumorigenesis and can thus form the basis of novel strategies for cancer therapy.",
author = "Shanmugam, {Muthu K.} and Frank Arfuso and Surendar Arumugam and Arunachalam Chinnathambi and Bian Jinsong and Sudha Warrier and Wang, {Ling Zhi} and Kumar, {Alan Prem} and Ahn, {Kwang Seok} and Gautam Sethi and Manikandan Lakshmanan",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23356",
language = "English",
volume = "9",
pages = "11414--11426",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "13",

}

Shanmugam, MK, Arfuso, F, Arumugam, S, Chinnathambi, A, Jinsong, B, Warrier, S, Wang, LZ, Kumar, AP, Ahn, KS, Sethi, G & Lakshmanan, M 2018, 'Role of novel histone modifications in cancer', Oncotarget, vol. 9, no. 13, pp. 11414-11426. https://doi.org/10.18632/oncotarget.23356

Role of novel histone modifications in cancer. / Shanmugam, Muthu K.; Arfuso, Frank; Arumugam, Surendar; Chinnathambi, Arunachalam; Jinsong, Bian; Warrier, Sudha; Wang, Ling Zhi; Kumar, Alan Prem; Ahn, Kwang Seok; Sethi, Gautam; Lakshmanan, Manikandan.

In: Oncotarget, Vol. 9, No. 13, 01.01.2018, p. 11414-11426.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Role of novel histone modifications in cancer

AU - Shanmugam, Muthu K.

AU - Arfuso, Frank

AU - Arumugam, Surendar

AU - Chinnathambi, Arunachalam

AU - Jinsong, Bian

AU - Warrier, Sudha

AU - Wang, Ling Zhi

AU - Kumar, Alan Prem

AU - Ahn, Kwang Seok

AU - Sethi, Gautam

AU - Lakshmanan, Manikandan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oncogenesis is a multistep process mediated by a variety of factors including epigenetic modifications. Global epigenetic post-translational modifications have been detected in almost all cancers types. Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence. These epigenetic modifications occur in key oncogenes, tumor suppressor genes, and transcription factors, leading to cancer initiation and progression. The most commonly observed epigenetic changes include DNA methylation, histone lysine methylation and demethylation, histone lysine acetylation and deacetylation. However, there are several other novel post-translational modifications that have been observed in recent times such as neddylation, sumoylation, glycosylation, phosphorylation, poly- ADP ribosylation, ubiquitination as well as transcriptional regulation and these have been briefly discussed in this article. We have also highlighted the diverse epigenetic changes that occur during the process of tumorigenesis and described the role of histone modifications that can occur on tumor suppressor genes as well as oncogenes, which regulate tumorigenesis and can thus form the basis of novel strategies for cancer therapy.

AB - Oncogenesis is a multistep process mediated by a variety of factors including epigenetic modifications. Global epigenetic post-translational modifications have been detected in almost all cancers types. Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence. These epigenetic modifications occur in key oncogenes, tumor suppressor genes, and transcription factors, leading to cancer initiation and progression. The most commonly observed epigenetic changes include DNA methylation, histone lysine methylation and demethylation, histone lysine acetylation and deacetylation. However, there are several other novel post-translational modifications that have been observed in recent times such as neddylation, sumoylation, glycosylation, phosphorylation, poly- ADP ribosylation, ubiquitination as well as transcriptional regulation and these have been briefly discussed in this article. We have also highlighted the diverse epigenetic changes that occur during the process of tumorigenesis and described the role of histone modifications that can occur on tumor suppressor genes as well as oncogenes, which regulate tumorigenesis and can thus form the basis of novel strategies for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85042166200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042166200&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23356

DO - 10.18632/oncotarget.23356

M3 - Review article

AN - SCOPUS:85042166200

VL - 9

SP - 11414

EP - 11426

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -

Shanmugam MK, Arfuso F, Arumugam S, Chinnathambi A, Jinsong B, Warrier S et al. Role of novel histone modifications in cancer. Oncotarget. 2018 Jan 1;9(13):11414-11426. https://doi.org/10.18632/oncotarget.23356